Clinical trial · Interventional
Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer
A Single-center, Prospective, Phase II Study of Albumin-bound Paclitaxel (Nab-paclitaxel) and Carboplatin With or Without Trastuzumab (Herceptin) as Neoadjuvant Therapy in Locally Advanced Breast Cancer
NCT01625429CI-TRIAL-00008462unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single-center, prospective, single arm phase II study to evaluate the efficacy and safety of nab-paclitaxel plus carboplatin (with trastuzumab for HER-2 positive patients) as neoadjuvant therapy in operable locally advanced breast cancer patients. The primary objective is pCR. The secondary objectives include ORR, 3-yr DFS, OS and safety. The sample size is 30.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| nab-paclitaxel | Drug | Nab-paclitaxel | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- neoadjuvant
- interventionNames
- Drug: nab-paclitaxel
Primary outcomes (1)
- measure
- Pathological complete response rate
- timeFrame
- Obtained within six months of the last patient's enrollment
- description
- The percentage of patients with a pathological complete response after neoadjuvant therapy
Secondary outcomes (4)
- measure
- Overall response rate
- timeFrame
- Obtained within six months of the last patient's enrollment
- description
- The percentage of patients with complete response or partial response after neoadjuvant therapy
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Female, between 18 and 70 years old * Life expectancy is more than 12 months * Breast MRI or ultrasound confirmd tumor over 3cm and biopsy comfirned invasive breast caner of stage II-III (inflammatory breast cancer excluded) * Not accompanied with other malignancies（except for controlled carcinoma in situ of the cervix or skin basal-cell carcinoma） * A normal bone marrow: absolute neutrophil count≥1.5\*10E9/L, hemoglobin≥100g/L, PLT≥100\*10E9/L * Normal liver and renal functions: AST≤60U/L, total biliruin≤1.5\*upper limit of normal, serum creatinine≤110umol/L, urea nitrogen≤7.1mmol/L * Normal blood coagulation function * ECOG performance status of 0-1 * Willing to coordinate with a punch biopsy before treatment and accept neoadjuvant therapy * Women of child-producing potential must agree to use effective contraceptive methods during the study, and a negative serum or urine pregnancy test must be obtained within 7 days prior to administration of the drugs * Written informed consent * For HER-2 positive patients, the HER-2 status must be determined by ICH +++ or FISH/CISH. For patients treated with trastuzumb, LVEF≥55% by ultrasonic cardiogram or MUGA scan Exclusion Criteria: * Previous systematic or local therapy including chemotherapy for breast cancer * Distant metastases of breast cancer are observed * Concurrent uncontrolled lung disease, severe sepsis, active peptic ulcer requring treatment, blood coagulation disorders, serious uncontrolled diabetes, connective tissue disease or bone marrow depression, unable to tolerate neoadjuvant therapy and related treatment * \>Grade 1 peripheral neuropathy caused by any reason * History of CHF, uncontrolled symptomatic angina, history of arrhythmias or myocardial infarction, poorly controlled hypertension (systolic pressure \> 180mmHg or diastlic pressure \> 100 mmHg) * Lactational or gestational breast cancer * Not willing to accept a punch biopsy before treatment and neoadjuvant therapy * Psychopath or any other reasons that would preclude compliane with treatment * Known serious allergy to any of the study drugs or excipients * Participation in another study requiring administration of an in investigational drug or biological agent at present or recently (within the last 30 days prior to screening visit)
References
Publications (0)
Data not yet available
No reference posted for this study.